Overview

• Brainstorm Cell Therapeutics Inc. is facing a class action lawsuit for allegedly misleading investors about the viability and efficacy of its drug, NurOwn.
• The lawsuit alleges that Brainstorm Cell downplayed the severity of the FDA's refusal to file a letter and concealed risks associated with the submission of the Biologics License Application (BLA).
• Several law firms, including Rosen Law Firm, Bragar Eagel & Squire, P.C., and Robbins LLP, are reminding investors of the upcoming lead plaintiff deadline on January 2, 2024.
• Brainstorm Cell's share price fell significantly following the FDA's refusal to file a letter and the subsequent announcement of the FDA's review results.
• Brainstorm Cell is a biotechnology company that develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases.